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Abstract
Leukopenia is an essential part of the clinical course of acute radiation sickness 
and is a side effect of anti-cancer treatment. In both situations, the main factors 
which determine the survival are the degree of bone marrow suppression and 
gastrointestinal tract damage due to the presence of a large pool of fast-dividing 
cells. Leuko- and neutropenia are main limiting factors which may contribute to 
chemotherapy failure. Hematopoietic cytokines the part of conventional therapy 
in this field, but their effects require boosting. That is why the use of means and 
methods of adsorption therapy is considered promising. Sorption therapy creates 
a basis for sorption detoxification, a doctrine of curative measures directed to the 
removal of toxic endogenous or exogenous compounds from body fluids. The most 
widely used types are the purification of blood or its components (hemosorption), 
oral administration of sorption materials (enterosorption) and application-sorption 
therapy of wounds and burns. In this chapter, the results of early and recent 
research and prospects for the use of carbon adsorption therapy for the treatment of 
acute radiation sickness and cytostatic myelosuppression are discussed.
Keywords: leukopenia, ionizing irradiation, anti-cancer chemotherapy,  
granulocyte colony stimulating factor, hemosorption, enterosorption,  
application-sorption therapy
1. Introduction
The danger of acute and chronic radiation injuries, which provoke leukopenia, 
is not just a myth today. The explosion at Unit 4 of Chernobyl Nuclear Power Plant 
(NPP) in 1986 showed how unprepared people were to such a problem. The collec-
tive dose of irradiation for liquidators (clean-up workers) was huge; no one knows 
the exact numbers (all dosimetric equipment measured only gamma irradiation). 
And until today, about five million people, who live in areas of Belarus, the Russian 
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Federation and Ukraine, which are contaminated with radionuclides, still experi-
ence the consequences of pollution [1–3]. An earthquake and tsunami struck 
Fukushima Dai-ichi NPP in 2011 contaminated the soil and water with radioactive 
cesium, iodine, etc. It poses significant risks of exposure to the residents [4, 5]. 
Terroristic threats or military conflicts with the use of radioactive weapons could be 
considered as a potential risk of injuries also.
One more source of contact with myelosuppressive factors is radiation therapy, 
which is routinely used in oncology (up to 70% of patients with malignant tumors 
are treated with) as well as anti-cancer chemotherapy with cytostatics [6–8]. 
Medical use of radiation accounts for 98% of the population dose contribution 
from all artificial sources and represents approximately 20% of the total exposure. 
Annually worldwide, more than 3600 million diagnostic radiology examinations are 
performed, 37 million nuclear medicine procedures are carried out and 7.5 million 
radiotherapy treatments are given [9]. In spite of side effects, the concomitant use 
of radiotherapy and chemotherapy resulted in significantly improved clinical out-
comes [10–12]. Different radiomimetics have effects similar to ionizing irradiation. 
Among them, a lot of anti-cancer drugs and leukopenia is a common side effect of 
dose-dense and dose-intense tumoricidal chemotherapy.
The organs and tissues with high speed cell proliferation is the most sensi-
tive for radiation- and radiomimetic damage. Leukopenia, because of aggressive 
direct ionizing irradiation or anti-cancer chemotherapy with cytostatics, is an 
important prognostic factor for overall survival [13, 14]. The association between 
chemotherapy-induced leukopenia and clinical outcome has been reported for 
several types of cancer. The development of such health impairments gains more 
and more attention, especially after the success of modern techniques such as stem 
cell transplantation and cytokine treatment to restore hematopoietic functions. But 
even now, it is not enough for the treatment of acute radiation sickness.
In last decades, we observe combined injury by ionizing radiation and toxic 
effects of xenobiotic, thermal burns, mechanical trauma, etc. Despite significant 
achievements in oncology, precise and targeted irradiation of tumors, the develop-
ment of effective means for enhancement of bone marrow cell and peripheral blood 
cells proliferation (granulocyte colony stimulating factors (G-CSF), erythropoietin, 
interleukin-11 and others), the problems of fighting the negative consequences of 
ionizing radiation and radiomimetics remain very important.
In this chapter, the results of early and recent research and prospects for the 
use of carbon adsorption therapy for the treatment of myelosuppression caused by 
acute radiation sickness and cytostatics use are discussed.
2. About radiation injuries
Acute radiation syndrome is a definition to reflect severe damage to specific 
organs that occurs because of whole-body or significant partial-body irradiation 
greater than 1 Gy, over a short time period (high dose rate) [15]. The main syndromes 
are hematopoietic (doses >2–3 Gy), gastrointestinal (doses 5–12 Gy) and cerebrovas-
cular one (doses 10–20 Gy) [16]. Depending on exposed and absorbed doses and its 
duration, cells exposed to ionizing radiation or radiomimetics present DNA muta-
tions, apoptosis, necrosis, chromosomal aberrations or increased mutation frequency 
[17, 18]. The most profound injury is to lymphoid organs (lymphatic nodes, spleen 
and thyroid gland), bone marrow, testicles, ovaries, gastrointestinal mucosa. 
Parenchymal organs, namely liver, adrenal glands, kidneys, salivary glands and lungs 
possess quite high radioresistance. According to World Health Organization (WHO), 
acute radiation sickness (ARS) is composed of the hematopoietic subsyndrome 
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(HS), gastrointestinal subsyndrome (GIS), neurovascular subsyndrome (NVS) and 
cutaneous subsyndrome (CS) [19]. The main factors which determine the survival of 
victims are the degree of bone marrow suppression and gastrointestinal tract dam-
age due to the presence of a large pool of fast-dividing cells [20–22]. Acute radiation 
sickness (ARS) could be considered as a sequence of immediate radiation injury and 
long-lasting bystander cross-effects.
Management of patients with ARS includes early use of hematopoietic cyto-
kines, antimicrobials and transfusion support; in addition, antiemetic agents and 
analgesics, and even hematopoietic stem cells transplantation [16, 23]. Since 1997, 
granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage 
colony-stimulating factor (GM-CSF) are used and their doses are driven by the 
radiation dose and physiologic responses for ARS [24] and by clinical protocols for 
leukopenia and neutropenia caused by anti-cancer treatment [25, 26]. However, 
these drugs still are of high cost, and pharmacoeconomic benefits seem to be 
questionable [27]. Singh et al. concluded that cytokine therapy has significant but 
modest effects [28]. All these facts force the researches to search new methods and 
means for additions to the management of post-aggressive iatrogenic leukopenia 
and related ARS- and radiomimetic-induced damage.
3. Adsorptive hemoperfusion therapy for ARS
Sorption detoxification types, quite widely used today in medicine, are: (1) 
hemoperfusion (when blood is filtered through the column with activated carbon); 
(2) enterosorption—enteral use of oral adsorbents of a different type and (3) 
application-sorption therapy - use of carbon dressing for the healing of the burns 
and wounds.
The ground for use of direct perfusion of the blood through an adsorbent col-
umn for its purification (hemoperfusion) was the Kuzin A.M. Structural-Metabolic 
Theory in Radiobiology (1970) [29]. Organs and tissues exposed to ionizing radia-
tion and radiomimetic influences are damaged by radiotoxins, which affect radio-
sensitive structures, and direct radiation-dependent changes in the macromolecules 
of the genome. Further investigations demonstrated that “radiotoxins” are reactive 
oxygen species (ROS) formed by water radiolysis. Oxidative stress causes DNA, 
protein and lipid oxidation and is responsible for the whole range of signs and 
syndromes of ARS [29]. Because of excessive lipid peroxidation, a lot of damaged 
cells appear that deepens the primary radiation injury repeatedly. In summary, ARS 
is a sum of primary damage due to oxidative stress plus so-called bystander effects 
[18], when cells exposed to ionizing radiation or radiomimetics can release signals 
that induce very similar effects on non-targeted neighboring cells.
Our first research of adsorptive therapy effects for acute radiation sickness (ARS) 
started in 1976 [30]. In this study, 69 inbred dogs were irradiated by external X-ray 
at the dose of 525 Rad (5.25 Gy). They were randomly assigned to three groups: first 
control group (n = 31), which received standard antibiotics therapy; second group 
(n = 19) got antibiotics + hemoperfusion 2 hours after irradiation and third group 
(n = 19) underwent saline infusion 4–5 hours after irradiation plus furosemide, and 
hemoperfusion 24 hours later. The results are presented in Table 1.
The highest survival rate was in the second group—68.4%, while in the con-
trol group, it was only 3.2%. Late hemoperfusion also resulted in a high survival 
rate—62.4%. Only 16% of an animal with hemoperfusion treatment (three dogs in 
each group) had critical leukopenia. In the control group, it was 93.5% of animals.
It is noteworthy, that mitotic index (a marker of the rate of cells division) 
(Figure 1) was significantly higher in the second group compared to the control one 
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(6 hours after irradiation) and even to the initial level (14th day after exposure to 
ionizing irradiation) [31].
Hemoperfusion with activated carbon also provided survival of 50% of 
dogs exposed to ionizing irradiation at the doses of 3.46 and 3.65 Gy [32]. 
These results were re-tested and developed within a special closed program of 
Research institutions of the Ministry of Health and the Ministry of Defense of 
USSR. Hemoperfusion methods were implemented into clinics [33, 34].
A team of researchers who carried out the experiment on dogs by irradiating 
them at the dose of 5.25 Gy, witnesses that perfusions of the blood through the col-
umn with a carbon adsorbent were quite short. Slugging of columns was the main 
reason for incomplete procedures (only 0.3-0.5 of circulating blood volume was 
purified) [35]. Despite these factors, the survival rate and other studied parameters 
were quite successful. We suppose that it could be explained by washout of dust 
particles from the surface of the adsorbent in the moment of primary contact with 
the blood, and viscosity changes inside the column after the replacement of rinsing 
solution to the blood also contributed to it. We think that positive secondary effects 
could be provided by nano- and microparticles (1–2 μ) of activated carbon, which 
contact with the blood. Their content is not controlled according to the standards of 
British (BP) and American (USP) Pharmacopeia.
Today, we have a lot of evidence that positive curative effects of carbon nanopar-
ticles, alone or as a part of a composite, are obliged to their ability to scavenge the 
ROS and simulate suppose the effects of free oxygen radical scavenging enzymes. 
Sandhir R. et al. [36] believe that nanoantioxidants (inorganic nanoparticles 
possessing intrinsic antioxidant properties) would be more effective against 
Figure 1. 
Mitotic index (‰) in the bone marrow of the dogs, exposed to external ionizing and hemoperfusion.  
Notes: * p ≤ 0.05 compared to the initial level; ** p ≤ 0.05 compared to the control group.
Group Survival 
rate, %
Animals with critical hematological indices, %






1 (n = 31) 3.2 13.4 ± 1.1 93.5 70
2 (n = 19) 68.4 17.0 ± 1.6 16.0 52.6
3 (n = 19) 62.4 16.6 ± 1.9 16.0 38.9
Table 1. 
Hemoperfusion for ARS treatment [30].
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ROS-induced damage because they cross the blood-brain barrier. It is a potential 
application in treating and preventing neurodegenerative conditions [36]. Arifa 
R.D. et al. research demonstrated that nanocomposite with fullerol decreases the 
intensity of irinotecan-induced leukopenia and gastrointestinal damage in mice and 
do not diminish the tumoricidal effects of the drug [37]. The aftertreatment with 
the same nanocomposite ameliorates the graft-versus-host disease reactions in mice 
and reduces intestinal lesions and bacterial translocation; prevents mortality and 
morbidity [38]. Nano-fullerenes promote osteogenesis of human adipose-derived 
stem cells and possess a great antioxidant capacity [39].
Encouraging results have been found concerning the amelioration of side effects 
of one more radiomimetic—anthracycline antibiotic doxorubicin (DOX), which 
also is known by its ability to cause oxidative stress and leukopenia. Fullerenol 
C60(OH)24 nanoparticles improved the myocardial morphology of DOX-treated 
animals, but cause a certain degree of parenchymal degeneration by itself [40]. 
Such and similar cases [41] evidence the need for designing and searching for the 
nanocomposites with specific features, which will possess antioxidant capacity 
without notable cytotoxicity. One of the solutions could be the conjugation of 
carbon nanomaterials with albumin [42]. It was found that C60(OH)24 decreases the 
consequences of DOX-induced excessive oxidation in the tissues of kidneys, testis 
and lungs in mice [43]. An aqueous solution of fullerenol was quite effective to fight 
experimental arthritis in rats [44]. Andrievsky G.V. et al. demonstrated significant 
(but only by 15%) radioprotective properties of hydrate C60 fullerene in X-ray irra-
diation of the mice at the lethal dose of 7 Gy [45]. Water-soluble polyvinilpyrroli 
done-wrapped fullerene derivative showed to significantly inhibit UVA-promoted 
melanogenesis in normal human epidermis melanocytes and human melanoma 
HMV-II cells within a non-cytotoxicity dose range [46]. Huq R. et al. showed that 
nontoxic poly(ethylene glycol)-functionalized hydrophilic carbon clusters, known 
scavengers of the ROS superoxide and hydroxyl radical, are preferentially internal-
ized by T lymphocytes over other splenic immune cells [47]. It was successfully 
used to reduce T-lymphocyte-mediated inflammation in experimental autoimmune 
encephalomyelitis (an animal model of multiple sclerosis) [47].
Another type of carbon material—carboxylated nanodiamonds, diminish the 
biochemical and histological signs of damage of γ-irradiated human erythrocytes [48]. 
On the other hand, hydrogenated nanodiamonds dramatically increase the sensitivity 
to radiation effects of human radioresistant cancer cell lines [49]. The same effect was 
seen considering the radiomimetic neocarcinostatin. Single-walled carbon nanotubes 
were found to be the efficient nanocarriers for drug delivery in the murine model of 
breast cancer [50, 51]. The team of researchers [52] synthesized the magnetic particles 
Fe3O4 in the shell from partially graphitized carbon and demonstrated their high 
intrinsic peroxidase-like catalytic activity, which promotes oxidative stress in human 
prostate cancer PC-3 cells in the presence of ascorbic acid. One more interesting study 
with a composite system of reduced graphene oxide—iron oxide nanoparticles showed 
that such a combination can synergistically induce physical and chemical damage to 
methicillin-resistant Staphylococcus aureus (MRSA) [53].
We must notice, that carbon nanoparticles possess great antioxidant properties 
and could be perspective for designing the nanopharmaceutical means and drugs 
to treat the disorders, when oxidative stress is an intrinsic part of pathogenesis, for 
leukopenia also. It means that further studies of carbon micro- and nanoparticles 
effects at parenteral routes of administration could finalize the discovery of quite a 
new method of mass treatment of acute radiation sickness.
Recently, several detailed reviews have been published on the pharmacological 
potential and prospects for the therapeutic use of cerium nanoparticles as traps of 
highly reactive oxygen (ROS) and nitrogen species (RNS) [54–56]. These reviews 
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are based on a variety of experimental studies both in vitro and in vivo. Not less 
interesting results for use of nanocrystal cerium dioxide (CeO2) on the model of 
DOX-induced cardiomyopathy in rats we got [57]. Cardiomyocytes mostly are  
damaged because of the radiomimetic impact of the drug, and the violation of 
blood components was quite similar to the effects of ionizing irradiation. It is 
known that oxidative stress is an intrinsic part of the cytotoxic effects of DOX, and 
heart tissues are vulnerable because of a lack of intracellular antioxidant defense 
factors compared to other organs and systems [58].
In this study, we used 21 female white mongrel rats, which were randomly 
assigned to the next groups (n = 7): first control groups got weekly intraperitoneal 
(IP) injection of saline; rats of second (DOX) and third groups got three times a week 
IP injections of doxorubicin at a dose of 2.5 mg/kg (n = 7); rats of third (DOX + CeO2) 
group got twice weekly IP injections of nanodisperse CeO2 (0.2 mg/kg) next day after 
doxorubicin injections additionally. Treatments lasted for 2 weeks (Figure 2).
Injections of nanodisperse CeO2 caused positive changes in myocardium 
structure. We observed improvement of a structure, decreased vacuolization of 
sarcoplasm, a number of cells with nuclei pathology was much lower (Figure 4) 
compared to the second group (Figure 3). A part of myocardium cells still had 
pyknotic nuclei with karyolysis signs. But mostly, the intensity of dystrophy and 
necrosis reduced and nuclei acquired oval shape again.
Figure 3. 
Myocardium tissue of rat of the DOX group. H&E. ×600.
Figure 2. 
Myocardium tissue of rat of the control group. H&E. ×600.
7Sorption Detoxification as an Addition to Conventional Therapy of Acute Radiation Sickness…
DOI: http://dx.doi.org/10.5772/intechopen.85690
Also, we observed an increased number of lymphoid follicles in the spleen, 
which restored a circle-like shape (Figures 5–7).
There were no significant positive changes in the structure of liver parenchyma. 
We may just note restoring nuclei sizes and shape and a little bit lighter pale pink 
Figure 4. 
Myocardium tissue of rat of the DOX + CeO2 group. H&E. ×600.
Figure 5. 
Spleen structure of rat of the control group. H&E. ×600.
Figure 6. 
Spleen structure of rat of the DOX group. H&E. ×600.
Cells of the Immune System
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Figure 7. 
Spleen structure of rat of the DOX + CeO2 group. H&E. ×600.
color of cytoplasm. It witnesses that the synthetic function of the liver was partly 
restored. Concerning the kidneys, no positive changes had been found.
Biochemical indices of lipid and protein peroxidation, antioxidant defense  
system showed that CeO2 increased the activity of catalase by 24.6%, raised the 
level of reduced glutathione by 10.9% and decreased the level of oxidative modifi-
cation of protein and lipids by 28.1 and 23.6%, respectively (compared to the group 
with untreated DOX-induced cardiomyopathy).
Bakht M.K. et al. proposed to reduce the actual radiation burden in patients 
exposed to radioisotope studies by arranging radiolabels for cerium oxide [59], and 
Colon J. et al. could achieve a good prophylactic result for radiation pneumonitis 
in mice that received nanocrystalline dioxide Ce [60]. One more fact should be 
mentioned here: because of bone marrow suppression and leukopenia develop-
ment, lungs are fragile to injury by ionizing irradiation. They have their own host 
defense system, based on alveolar macrophages. Because of leukocytes toxic damage 
(by ionizing injury or radiation therapy or as the side effects of anti-cancer chemo-
therapy), resting macrophages can no longer be transformed which lead to radia-
tion pneumonitis [24]. Heslet L. et al. showed that systemic administration of myelo 
stimulative cytokines was not helpful to prevent it because they do not penetrate the 
alveoli. That is why we suggest that oral adsorbents and/or parenteral use of CeO2 
(it penetrated the alveoli and prevents radiation pneumonitis on mice model) will 
enhance the prophylaxis and treatment of ARS and decrease the intensity of side 
effects of radiation therapy and cytostatic drugs.
4.  Local signs of whole-body irradiation and efficacy of  
application-sorption therapy
External exposure to ionizing irradiation frequently results in radiation burns of the 
skin. Leukopenia just deepens the injury because of oppressing the regeneration pro-
cesses. A retrospective report on injuries caused by the atomic bombing of Hiroshima 
showed that up to 65% of all type of injuries were “radiation-combined injury,” when 
ionizing irradiation was coupled with burns, wounds and infections [61]. Regarding 
these facts and negative contribution of leukopenia also, we want to demonstrate the 
efficiency of activated carbon. The remarkable result was observed on the model of 
the thermal non-full depth burn in Albino rats [62]. The early application (within first 
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60 min) of the highly active carbon fabrics (SBET > 2000 m
2/g) twofold reduced the 
healing time: 10.80 ± 1.27 and 20.60 ± 0.86 days for adsorptive carbon and gauze dress-
ings use, respectively (Figure 8).
Histological analysis demonstrated that adsoptive carbon dressings’ application 
promoted the restoration of skin structure on the 7th day after injury in rats with 
the non-full burn (Figures 9–11).
Similar results were observed on the burns caused by external irradiation at the 
dose of 8 Gy. Epithelialization of burn wounds has been completed on 21.1 ± 4.1 ver-
sus 27.3 ± 5.7 days after trauma for carbon and gauze dressings use, respectively. One 
Figure 8. 
The dynamics of healing of the non-full depth burn after application of the gauze and carbon dressing.
Figure 9. 
Morphological structure of normal skin. H&E. ×200.
Figure 10. 
Morphological structure of burned skin after use of gauze dressing on the 7th day after the thermal non-full 
depth burn. H&E. ×200.
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Figure 11. 
Morphological structure of the burned skin after use of carbon dressing on the 7th day after the thermal  
non-full depth burn. H&E. ×200.
more fact relates to the treatment ultraviolet radiation-induced burns. Application 
of adsorptive carbon dressings significantly (by 1.5–1.7 times) accelerated the burn-
healing time. All these data will be published soon.
These results presented the undoubted perspective for use of high capacity 
carbon fabrics for the treatment of superficial skin lesions, especially complicated 
by concomitant leukopenia.
5. Enterosorption for leukopenia management
Hemoperfusion as a procedure requires well-trained staff, specific equipment and 
sterility. It means that such method of sorption detoxification is not adapted to emer-
gency exposure situations, during war-time and large human contingent injury. That 
is why the use of enteral sorption therapy (ingestion of activated carbon) is a more 
prospective method for such situations. Among the early studies, the great results 
were observed in the patients with lymphogranulomatosis undergoing radiotherapy 
[63], who were treated with fibrous carbon oral adsorbent. Enterosorption treatment 
allowed to continue planned schemes of radiation therapy and was more efficient than 
conventional methods for leukopenia healing. In the next study [64], cyclophosphane 
was given to Guerin tumor-grafted rats at the dose of 100 mg/kg of body weight on 
10th and 13th days after tumor transplantation; enterosorption with synthetic SCN 
carbons (bulk density 0.3–0.4 g/cm3) was administered next day after cyclophosphane 
injection. These expressed myeloprotective effects we approved and confirmed in 
the clinic. One more radiomimetic anti-cancer agent cisplatin was used in an experi-
ment on Guerin tumor-grafted rats [65] and highly activated fibrous carbon material 
Carboline (Ukraine) successfully ameliorated a wide range of its side effects. Carboline 
is used in clinical practice also and demonstrates promising results [66].
Our latest experiments on rats exposed to X-ray irradiation in a total dose of 
6 Gy (63 Rad per min, t = 11 min) demonstrated great results of novel oral carbon 
adsorbents administration to ameliorate radiation-caused leukopenia. We used two 
granulated activated carbons (AC) with a diameter of granules (0.25–0.5 mm) and 
bulk density 0.1 and 0.2 g/cm3 (ES1 and ES2, respectively). Enterosorbents were 
administrated as radioprotectors, radiomitigators and therapeutic agents (at the 
dose of 10 ml/kg, admixed to the food, three days before and nine days after ion-
izing irradiation exposure). Irradiation caused a 10-fold decrease in the white blood 
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cells count. ES1 administration raised the index twice on the 9th day after X-ray 
exposure, while ES2 produced fewer results (Figure 12).
The same effect was observed concerning the lymphocytes count (Figure 13). 
Structural differences among those two carbon adsorbents are estimated. These 
results will be published soon in detail.
So, as we observed, specific oral adsorbents with specified porosity and pores 
distribution are quite successful to fight the iatrogenic leukopenia because of the 
influence of ARS or anti-cancer treatment.
Oral carbon materials have a high capability to decrease the emesis caused by 
anti-cancer treatment [66, 67]. Also, it is a unique mean with anti- 
diarrhea action, which could be implemented in the clinics for the treatment of 
ARS-induced gastrointestinal subsyndrome as well as for dyspepsia syndrome 
caused by tumoricidal therapy.
Thus, enterosorption for the results on the animal study and use in clinics do 
prevent hematotoxicity of anti-cancer treatment and significantly ameliorated 
leukopenia and its consequences.
Figure 12. 
White blood cells count (109/L) in X-ray irradiation at the dose of 6 Gy and oral adsorbents administration. 
Notes: p < 0.05 compared to: *—the control group, **—X-ray irradiation group.
Figure 13. 
Lymphocytes count (109/L) in X-ray irradiation at the dose of 6 Gy and oral adsorbents administration.  
Notes. p < 0.05 compared to: *—the control group, **—X-ray irradiation group.
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6.  Oral carbon adsorbents as an addition to classical treatment of 
leukopenia with G-CSF
Abovementioned positive results led us to design of a new improved version of 
carbon oral adsorbent, which was used in early experiments [64, 68]. An old prototype 
C1 and his new version C2 were approved on the model of melphalan-induced bone 
marrow suppression [69–71]. We demonstrated that myeloprotective action of carbon 
granulated enterosorbent С1 (bulk density of 0.28 g/cm3, specific surface of 1719 m2/g 
and mesopore area of 239 m2/g) is significantly less compared to effects of adsorbent 
C2 with bulk density of 0.18 g/cm3, total specific surface of 2162 m2/g and mesopore 
area of 565 m2/g (Figure 14).
Figure 15. 
White blood cells count (109/L) on the 8th day after melphalan injection at the dose of 4 mg/kg and 
administration of oral carbon adsorbent and filgrastim in the study on rats. Notes. p < 0.05 compared to: *—
Control group; **—Melphalan group; ***—Melphalan + C2 group; ****—Melphalan + filgrastim group.
Figure 14. 
White blood cells and neutrophils counts (109/L) on the 8th day after melphalan injection at the dose of 3 mg/
kg and administration of oral carbon adsorbents C1 and C2 in a study on rats. Notes. *—p < 0.05 compared to 
the control group; **—p < 0.05 compared to the melphalan group; #—p < 0.05 and compared to the  
Melphalan + C1group.
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C2 enterosorbent administration normalized the prooxidant/antioxidant system 
indices too [71]. Oxidative stress is an intrinsic part of ionizing radiation and radio-
mimetic injury, and enteral sorption therapy possesses notable antioxidant effects.
Adding the carbon oral adsorbent to classical scheme for the treatment of leuko-
penia with G-CSF (caused by single intravenous melphalan injection at the dose of 
4 mg/kg) demonstrated significant myeloprotective effect and synergy compared 
to single-use effects of each agent alone [70] (Figures 15 and 16). C2 and filgrastim 
combination caused increase of white blood cells count by 138.3% compared to 
the melphalan group; by 65.8% compared to melphalan + C2 group, and by 51.7% 
compared to use of filgrastim alone.
We must note that in this study, we got an unexpected significant increase of 
platelets level from (254.60 ± 45.59) to (505.40 ± 70.68) × 109/L in a group of rats 
that received the combined treatment with oral adsorbent and G-CSF. Isolated 
administration of enterosorbent C2 tended to raise the level of thrombocytes, we 
suppose because of general detoxification action.
Use of enterosorbent or combined use of both preparations provided signifi-
cantly better effects toward the prooxidant/antioxidant balance in rats.
The important issue is that combination of G-CSF and carbon adsorbents [69] 
as well as enteral sorption therapy use alone [65] does not affect the efficacy of anti-
cancer treatment; we proved it by our experiments on Guerin tumor-grafted rats.
7. Conclusions
Leukopenia is an essential part of the damage caused by ionizing irradiation 
and/or radiomimetic influences (as tumoricidal chemotherapy). Leukocytes play an 
important role in immune defense, tissue regeneration, the functioning of the main 
organs and systems; and the degree of bone marrow suppression determines the 
survival of victims in ionizing radiation exposure as well as the efficacy of anti-
cancer chemotherapy. All three methods of sorption detoxification with activated 
carbons such as hemoperfusion (when blood is filtered through the column with 
activated carbon); enterosorption—peroral use of oral adsorbents and application-
sorption therapy (use of carbon dressing for the healing of the burns and wounds), 
can be successfully used for the leukopenia prophylaxis and treatment in ionizing 
irradiation exposure, side effects of anti-cancer chemotherapy, as well as for the 
boosting of healing of associated skin damage.
Figure 16. 
Neutrophils count (109/L) on the 8th day after melphalan injection at the dose of 4 mg/kg and administration 
of oral carbon adsorbent and filgrastim in a study on rats. Notes. p < 0.05 compared to: *—Control group; 
**—Melphalan group.
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provided the original work is properly cited. 
Enterosorption demonstrates significant synergy with hemopoietic cytokines in the 
treatment of bone marrow suppression caused by such an aggressive agent as melpha-
lan (a derivative of mustard nitrogen). Nanocrystal cerium dioxide could be useful for 
oxidative stress modulation caused by such radiomimetic as anti-cancer anthracycline 
antibiotic doxorubicin. Modification of pathological biochemical processes which 
provoke bone marrow suppression and leukopenia is a basis of the efficacy of sorption 
detoxification in acute radiation syndrome as well as to decrease the side effects of 
anti-cancer chemotherapy. Our findings may contribute to the refinement of current 
risk stratification algorithms for acute radiation sickness treatment.
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